Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Nalorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalorphine SCHEMBL6908593 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL16015635 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL17771837 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL19199030 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12091243 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12230555 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12030798 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL14124636 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL38920 | 0.99 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL149571 | 0.98 | OPRM1 (0.98) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | MENLO THERAPEUTICS INC. (US) | 2019-07-18 | — | — | US | claimed |
| EP-3478283-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | Menlo Therapeutics Inc. (US) | 2019-05-08 | — | — | EP | claimed |
| CN-109640981-A | Neurokinine-1 antagonist is used to treat the purposes of a variety of pruritic conditions | 曼隆治疗公司 | 2019-04-16 | — | — | CN | claimed |
| WO-2018005695-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | MENLO THERAPEUTICS INC. (US) | 2018-01-04 | — | — | WO | claimed |
| CN-1653050-A | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES INC (US) | 2005-08-10 | — | — | CN | claimed |
| EP-0154639-B1 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE REDUCING ACTIVITY AND A PROCESS FOR THEIR PREPARATION | BALKANYI, Iván (HU) | 1990-07-04 | — | — | EP | claimed |
| US-12637452-B2 | Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20250360163-A1 | Therapeutic Composition and Methods | VISCERA LABS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250144134-A1 | Therapeutic Composition and Methods | VISCERA LABS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-3880678-B1 | CRYSTALLINE FORMS OF P2X3 MODULATOR METHYL (S)-2-((2-(2,6-DIFLUORO-4-(METHYLCARBAMOYL )PHENYL)-7-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)METHYL)MORPHOLINE-4-CARBOXYLATE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 3 LTD (GB) | 2025-05-07 | — | — | EP | disclosed |
| US-12239660-B2 | Therapeutic composition and methods | VISCERA LABS, INC. | 2025-03-04 | — | — | US | disclosed |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240050464-A1 | Therapeutic Composition and Methods | VISCERA LABS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-0098742-B1 | METHOD AND APPARATUS FOR CUSTOMIZING A MULTI-STATION DOCUMENT INSERTER | PITNEY BOWES, INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4548395-A | Microfiche feeder | Snellman, Donald L. (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0154639-A1 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE REDUCING ACTIVITY AND A PROCESS FOR THEIR PREPARATION. | BALKANYI IVAN (HU) | 1985-09-18 | — | — | EP | disclosed |
| WO-1985000970-A1 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE REDUCING ACTIVITY AND A PROCESS FOR THEIR PREPARATION | BALKANYI IVAN | 1985-03-14 | — | — | WO | disclosed |
| US-4464378-A | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-08-07 | — | — | US | disclosed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | disclosed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239660-B2 | Therapeutic composition and methods | CETP, APOB, FABP2 | SIGMAR1 229/4885ADRA2A 651/4885OPRM1 700/4885 |
| US-20250144134-A1 | Therapeutic Composition and Methods | S100A6, FABP2, SLC10A2 | SIGMAR1 391/4885ADRA2A 826/4885OPRM1 335/4885 |
| US-20250360163-A1 | Therapeutic Composition and Methods | FABP2, GPR119, TTR | SIGMAR1 2282/4885ADRA2A 1607/4885OPRM1 2839/4885 |
| US-20240050464-A1 | Therapeutic Composition and Methods | CETP, APOB, FABP2 | SIGMAR1 229/4885ADRA2A 651/4885OPRM1 700/4885 |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | P2RX3, P2RX1, P2RX5 | SIGMAR1 348/4885ADRA2A 546/4885OPRM1 404/4885 |
| US-12637452-B2 | Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator | P2RX3, P2RX2, P2RX4 | SIGMAR1 51/4885ADRA2A 71/4885OPRM1 30/4885 |
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | BDKRB2, BDKRB1, PBK | SIGMAR1 494/4885ADRA2A 253/4885OPRM1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.